Efficacy and safety of different dosing regimens of HB0017, a novel humanized anti-interleukin-17A monoclonal antibody, in moderate-to-severe plaque psoriasis: a multicenter, randomized, double-blind, placebo-controlled, phase II study

This study demonstrated the promising efficacy of HB0017, and offers a new alternative for moderate-to-severe psoriasis, which might potentially improve patient compliance and treatment outcomes with less frequent dosing.